- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Robins Kaplan, Two Partners Shortlisted for LMG Life Sciences Awards
July 26, 2023
Robins Kaplan LLP is pleased to announce that Jake Holdreith and Oren Langer have been selected as finalists in LMG Life Sciences 2023 Americas Awards. Holdreith was named to the shortlist for General Patent Litigator of the Year – Midwest, while Langer was selected to the Hatch-Waxman Litigator of the Year – Generic shortlist. Additionally, the firm was shortlisted for Hatch-Waxman Litigation Firm of the Year – Generic.
Holdreith is a member of the firm’s executive board and the leader of the firm’s life sciences group. A skilled and creative strategist, he has tried jury cases to multi-million-dollar verdicts and resolved complex cases at all stages of litigation. Holdreith is known for his work in the pharmaceutical, chemical, and electronics industries and has handled cases in the United States, Europe, and Asia. Last year, Holdreith was named “Hatch-Waxman Litigator of the Year – Generic” and received the “Patent Impact Case of the Year” award from LMG Life Sciences. He has also been regularly recognized as a “Life Sciences Star.”
Langer serves as Managing Partner of the firm’s New York office. An accomplished patent litigator, he has worked extensively under the Hatch-Waxman regulatory framework. He’s examined and cross-examined fact and expert witnesses at nearly one dozen trials, representing a variety of clients, including Collegium Pharmaceutical, Inc., Amneal Pharmaceuticals, Inc., Hikma Pharmaceuticals USA, Inc., Torrent Pharmaceuticals Ltd., and Novel Labs. In 2022, among other accolades, Langer was named a recommended litigator in the IAM Patent 1000 and a “Life Sciences Star” by LMG Life Sciences.
You can find a complete list of the nominees here. The winners of this year’s awards will be announced at a ceremony in New York City on September 7, 2023.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.